NORTHVALE, N.J.--(BUSINESS WIRE)--Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (AMEX: ELI), has completed the first stage of its Phase II study for ELI-216 and is preparing to initiate the final stage. The initial study successfully demonstrated the euphoria-blocking effect of ELI-216. This study was designed to determine the optimal ratio of oxycodone hydrochloride and opioid antagonist, naltrexone hydrochloride, to significantly block the euphoric effect of the opioid if the product is abused.
